secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortress Biotech, Inc. (FBIO)
CIK:        0001429260
Form:       8-K
Filed at:   2025-07-16T23:59:59+00:00
Accession:  0001558370-25-009264
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Fortress' former asset anselamimab fails primary endpoint in Phase III CARES study
--------------------------------------------------------------------------------

- AstraZeneca announced anselamimab did not achieve statistical significance on primary endpoint (ACM + CVH hierarchy) in Mayo stages IIIa/IIIb AL amyloidosis.
- Prespecified subgroup showed 'highly clinically meaningful improvement' in ACM and CVH; AZ plans further evaluation and regulatory discussions.
- Fortress remains eligible for up to ~$125M in milestones from the 2021 Caelum sale; outcome reduces likelihood of near-term payments.
- Anselamimab was well-tolerated; detailed results to be presented at future medical meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1429260/000155837025009264/0001558370-25-009264-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1429260/000155837025009264/fbio-20250716x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-009264

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer